Trial Profile
BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 Feb 2022 Status changed from completed to discontinued.
- 25 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.